{"eventGroups":[{"description":"Bortezomib was administered SC at a dose of 1.0 mg/m2. Doses were administered on days 1, 4, 8, and 11 of a 28-day cycle. When administered subcutaneously, sites for each injection (thigh or abdomen) were rotated and reported. All other drugs used in combination with the SC bortezomib were recorded in the Case Report Forms along with their corresponding doses and schedules.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":2,"seriousNumAtRisk":5,"title":"Subcutaneous Bortezomib"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Neturopenia Gr3","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5,"numEvents":2}],"term":"Gr3 Neturopenia"}]}